Macrophage Activation Syndrome Clinical Trial
Official title:
Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis
The pathophysiology of macrophage activation syndrome has been mainly studied in pediatric genetic primary forms. There is little data in secondary forms related to bacterial sepsis. Because of the seriousness of this entity (43% of deaths in intensive care in the largest cohort published so far by the medical resuscitation team of Rouen University Hospital), it is necessary to better understand the physiopathological mechanisms to be able to propose a suitable therapy. For now, the management of this syndrome is far from consensual. Some authors advocate a single etiological treatment, while others suggest the need for intensive management of anti-inflammatory and immunosuppressive type. The fragility of resuscitation patients does not allow intensive immunosuppressive therapies as proposed by some authors. In the era of immunotherapy, the precise knowledge of physiopathological data would make it possible to propose a targeted therapy with little risk of adverse effects. Recent work has indeed shown excellent tolerance of immunotherapy during sepsis and could be applied eventually in patients with macrophage activation syndrome.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06405152 -
Assessment of Macrophage Activation syndromE in STill's Disease
|
||
Active, not recruiting |
NCT02780583 -
Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
|
Phase 1 | |
Active, not recruiting |
NCT01966367 -
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT01095146 -
New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome
|
N/A | |
Recruiting |
NCT06339177 -
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
|
||
Recruiting |
NCT02569463 -
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome(MAS)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05137496 -
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT03827343 -
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
|
||
Recruiting |
NCT05611710 -
Anakinra in Dengue With Hyperinflammation ( AnaDen )
|
Phase 2 | |
Completed |
NCT03311854 -
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
|
Phase 2 | |
Recruiting |
NCT05001737 -
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
|
Phase 3 | |
Completed |
NCT03332225 -
A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis
|
Phase 2 | |
Completed |
NCT04339712 -
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
|
Phase 2 |